Economy

PREDICTION BY

FOLLOW-UP

This is a multi-year forecast extending beyond 2025, and it is too early to determine the outcome. No information in the provided snippets confirms or denies this prediction.

PREDICTION BY

FOLLOW-UP

Wieser's December 2024 prediction of 4.5% growth for 2025 was subsequently downgraded to 3.6% by March 2025, confirming the prediction that he would 'tamp down' expectations for the new year (2025).

PREDICTION BY

FOLLOW-UP

While Wieser maintained his expectation of H2 2024 deceleration as of September 2024, the strong Q2 performance (9.6% growth) contradicted an *imminent* slowdown. The provided snippets do not contain actual realized Q3 and Q4 2024 growth figures to definitively confirm or deny the H2 deceleration.

PREDICTION BY

FOLLOW-UP

Wieser's March 2024 forecast of 5.6% growth for the U.S. ad industry in 2024 (excluding political) was later revised upward repeatedly to 7.2% by September 2024, indicating the actual performance was stronger than initially predicted in March.

PREDICTION BY

FOLLOW-UP

The prediction is for the year 2026, which has not yet occurred. There is no outcome available in the provided materials to evaluate this forecast.

PREDICTION BY

FOLLOW-UP

U.S. existing home sales remained muted relative to pre-pandemic levels; there was some improvement but not a 'boom' in sales volume.

PREDICTION BY

FOLLOW-UP

U.S. home sales volumes rebounded from 2023 lows, but the recovery was moderate rather than an unambiguous 'boom' due to continued inventory constraints and affordability issues.

PREDICTION BY

FOLLOW-UP

Headline and core U.S. inflation measures did fall materially through late 2024 and into 2025, with several readings in the low-2% range, broadly confirming the prediction of continued downward momentum and reaching below-2.5% levels.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs did become a major economic and media narrative, with substantial market-cap gains for pharma and widespread discussion of their impact across various sectors, aligning with Galloway's prediction of it being the defining 'tech of the year' economically.

PREDICTION BY

FOLLOW-UP

India's economy and its role in global growth expanded significantly in 2024, reaffirming its economic emergence spurred by demographic changes.

PREDICTION BY

FOLLOW-UP

The economic environment was slower growth with still-elevated prices, but not classic stagflation (simultaneous high inflation and flat/negative real growth). Real GDP remained positive, though "real" ad growth was modest.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year'.

PREDICTION BY

FOLLOW-UP

Throughout 2024-2025, the Hollywood ecosystem continued to experience struggles such as profitability pressures, restructurings, and cautious content spending, aligning with Galloway's prediction.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year.'

PREDICTION BY

FOLLOW-UP

India's digital economy and ad market experienced strong growth, with major platforms and global marketers increasing investment. India's macroeconomic growth outpaced many economies, supporting the prediction of its population growth registering in economic terms.